Alnylam Pharmaceuticals
ALNY
#561
Rank
HK$348.42 B
Marketcap
HK$2,627
Share price
-0.94%
Change (1 day)
34.57%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Operating Margin for Alnylam Pharmaceuticals (ALNY)

Operating Margin at the end of 2025: 8.70%

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is 8.70%. At the end of 2025 the company had an Operating Margin of 8.70%.

Operating Margin history for Alnylam Pharmaceuticals from 2003 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
20258.70%-151.84%
2024-16.79%-29.21%
2023-23.71%-78.17%
2022-108.63%7.63%
2021-100.93%-41.86%
2020-173.60%-56.91%
2019-402.85%-60.33%
2018-1,015.48%86%
2017-545.95%-37.22%
2016-869.63%23.21%
2015-705.83%-10.92%
2014-792.32%306.56%
2013-194.88%11.54%
2012-174.73%150.82%
2011-69.66%62.06%
2010-42.98%-8.07%
2009-46.76%76.12%
2008-26.55%-83.16%
2007-157.61%7.45%
2006-146.68%-80.71%
2005-760.53%0.84%
2004-754.18%-93.51%
2003-11,618.18%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Novartis
NVS
28.85% 231.61%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
15.12% 73.79%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
36.46% 319.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-10.44%-220.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-118.00%-1,456.32%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-24.83%-385.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
7.08%-18.62%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
6.21%-28.62%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.